BRPI0501542A - processo de obtenção de lignanas dibenzilbutirolactÈnicas, tetrahidrofuránicas e de seus derivados sintéticos e semi-sintéticos, suas atividades analgésica e antiinflamatória, formulações tópicas e/ou sistêmicas contendo tais lignanas e respectivo método terapêutico - Google Patents

processo de obtenção de lignanas dibenzilbutirolactÈnicas, tetrahidrofuránicas e de seus derivados sintéticos e semi-sintéticos, suas atividades analgésica e antiinflamatória, formulações tópicas e/ou sistêmicas contendo tais lignanas e respectivo método terapêutico

Info

Publication number
BRPI0501542A
BRPI0501542A BRPI0501542-1A BRPI0501542A BRPI0501542A BR PI0501542 A BRPI0501542 A BR PI0501542A BR PI0501542 A BRPI0501542 A BR PI0501542A BR PI0501542 A BRPI0501542 A BR PI0501542A
Authority
BR
Brazil
Prior art keywords
synthetic
lignans
semi
derivatives
obtaining
Prior art date
Application number
BRPI0501542-1A
Other languages
English (en)
Inventor
Marcio Luis Andrade E Silva
Jairo Kenupp Bastos
Paulo Marcos Donate
Sergio De Albuquerque
Rosangela Da Silva
Original Assignee
Fundacao De Amparo A Pesquisa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fundacao De Amparo A Pesquisa filed Critical Fundacao De Amparo A Pesquisa
Priority to BRPI0501542-1A priority Critical patent/BRPI0501542A/pt
Priority to PCT/BR2006/000084 priority patent/WO2006113981A2/en
Priority to JP2008508031A priority patent/JP2008539173A/ja
Priority to EP06721642A priority patent/EP1917260A4/en
Priority to US11/912,645 priority patent/US20080214661A1/en
Publication of BRPI0501542A publication Critical patent/BRPI0501542A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"PROCESSO DE OBTENçãO DE LIGNANAS DIBENZILBUTIROLACTÈNICAS, TETRAHIDROFURáNICAS E DE SEUS DERIVADOS SINTéTICOS E SEMI-SINTéTICOS, SUAS ATIVIDADES ANALGéSICA E ANTTINFLAMATóRIA, FORMULAçõES TóPICAS E/OU SISTêMICAS CONTENDO TAIS LIGNANAS E RESPECTIVO MéTODO TERAPêUTICO. A presente invenção refere-se a um processo de obtenção de lignanas dibenzilbutirolactónicas partindo-se de (-)-cubebina, isolada de uma Piperaceae, em especial, de Piper cubeba e de (-)-metilpluviatolido, isolado de uma Rutacea, em especial, de Zanthoxylum naranjillo; seus derivados sintéticos e semi-sintéticos e de lignanas tetrahidrofurânicas, tais como a galgravina e veraguensina, isoladas de Nectandra megapotamica, bem como as atividades analgésica e antiinflamatória destas lignanas, e as formulações tópicas e/ou sIstêmicas nas quais as lignanas perfazem 60 a 80% da formulação. A invenção também refere-se a um método terapêutico utilizando formulações tópicas e/ou sistêmicas a base de ditas lignanas no tratamento de inflamação e/ou dor. Mais especificamente, refere-se a um processo de obtenção de derivados sintéticos e semi-sintéticos de (-)-cubebina, tais como: (-)-O-acetilcubebina; (-)-O-metilcubebina; (-)-O-dimetiletilaminocubebina; (-)-hinoquinina; (-)-6,6<39>-dinitroinoquinina; (-)-O-benzilcubebina; (-)-6,6<39>-diaminolnoquinina e outros derivados sintéticos que venham a ser obtidos, e de derivados sintéticos e semi-sintéticos de (-)-6,6<39>-metilpluviatolido, tais como (-)-6,6<39>-dinitrometilpluviatolido e (-)-6,6<39>-diaminometilpluviatolido, para serem utilizados na fabricação de medicamentos que proporcionem atividade analgésica e antiinflamatória. A presente invenção refere-se ainda ao processo de obtenção das substâncias galgravina e veraguensina isoladas de Nectandra megapotamica, bem como, seus derivados sintéticos e semi-sintéticos com substituintes nos anéis aromáticos que vierem a ser obtidos.
BRPI0501542-1A 2005-04-28 2005-04-28 processo de obtenção de lignanas dibenzilbutirolactÈnicas, tetrahidrofuránicas e de seus derivados sintéticos e semi-sintéticos, suas atividades analgésica e antiinflamatória, formulações tópicas e/ou sistêmicas contendo tais lignanas e respectivo método terapêutico BRPI0501542A (pt)

Priority Applications (5)

Application Number Priority Date Filing Date Title
BRPI0501542-1A BRPI0501542A (pt) 2005-04-28 2005-04-28 processo de obtenção de lignanas dibenzilbutirolactÈnicas, tetrahidrofuránicas e de seus derivados sintéticos e semi-sintéticos, suas atividades analgésica e antiinflamatória, formulações tópicas e/ou sistêmicas contendo tais lignanas e respectivo método terapêutico
PCT/BR2006/000084 WO2006113981A2 (en) 2005-04-28 2006-04-28 Process to obtain dibenzylbutyrolactonic, tetrahydrofuranic lignans and their synthetic and semi-synthetic derivatives, their analgesic and anti-inflammatory activities, topical and/or systemic formulations containing said lignans and their respective therapeutic method
JP2008508031A JP2008539173A (ja) 2005-04-28 2006-04-28 ジベンジルブチロラクトンのリグナン、テトラヒドロフランのリグナン、およびそれらの合成および半合成の誘導体を得る方法、それらの鎮痛性および抗炎症性の活性、前記リグナンを含有する局所性および／または全身性の製剤、ならびにそれらの治療方法
EP06721642A EP1917260A4 (en) 2005-04-28 2006-04-28 METHOD FOR OBTAINING DIBENZYLBUTYROLACTONIC TETRAHYDROFURANIC LIGNANES AND THEIR SYNTHETIC AND HALBSYNTHETIC DERIVATIVES, THEIR ANALGETIC AND INFLAMMATORY EFFECTS, TOPICAL AND / OR SYSTEMIC FORMULATIONS CONTAINING SUCH LIGNANES, AND ITS RELATED THERAPEUTIC METHODS
US11/912,645 US20080214661A1 (en) 2005-04-28 2006-04-28 Process To Obtain Dibenzylbutyrolactonic, Tetrahydrofuranic Lignans And Their Synthetic And Semi-Synthetic Derivatives, Their Analgesic And Anti-Inflammatory Activities, Topical And/Or Systemic Formulations Containing Said Lignans And Their Respective Therapeutic Method

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0501542-1A BRPI0501542A (pt) 2005-04-28 2005-04-28 processo de obtenção de lignanas dibenzilbutirolactÈnicas, tetrahidrofuránicas e de seus derivados sintéticos e semi-sintéticos, suas atividades analgésica e antiinflamatória, formulações tópicas e/ou sistêmicas contendo tais lignanas e respectivo método terapêutico

Publications (1)

Publication Number Publication Date
BRPI0501542A true BRPI0501542A (pt) 2006-12-12

Family

ID=37215101

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0501542-1A BRPI0501542A (pt) 2005-04-28 2005-04-28 processo de obtenção de lignanas dibenzilbutirolactÈnicas, tetrahidrofuránicas e de seus derivados sintéticos e semi-sintéticos, suas atividades analgésica e antiinflamatória, formulações tópicas e/ou sistêmicas contendo tais lignanas e respectivo método terapêutico

Country Status (5)

Country Link
US (1) US20080214661A1 (pt)
EP (1) EP1917260A4 (pt)
JP (1) JP2008539173A (pt)
BR (1) BRPI0501542A (pt)
WO (1) WO2006113981A2 (pt)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075801A1 (pt) 2009-12-21 2011-06-30 Acef S.A. Cubebina, lignana dibenzilbutirolactólica, seus derivados semi-sintéticos e sintéticos, bem como outras lignanas e neolignanas como agente vasodilatador na terapia da disfunção erétil

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102451178A (zh) * 2010-10-29 2012-05-16 中国科学院上海药物研究所 二氢呋喃-2-酮类化合物在制备抗糖尿病及糖脂代谢药物中的用途
WO2014086379A1 (en) 2012-12-03 2014-06-12 Alpinia Laudanum Institute Of Phytopharmaceutical Sciences Ag Lignan compositions
JP7197908B2 (ja) * 2019-03-04 2022-12-28 株式会社ナチュファルマ琉球 骨減少性疾患の予防及び／又は治療用組成物
CN112979625A (zh) * 2021-02-03 2021-06-18 广西馨海药业科技有限公司 荜橙茄素的合成方法及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0201237A (pt) * 2002-03-25 2003-12-02 Fundacao De Amparo A Pesquisa Processo de obtenção de lignanas dibenzilbutirolactÈnicas, processo de obtenção de derivados sintéticos de lignanas ostentando atividades quimioprofilática e terapêutica antichagásica

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011075801A1 (pt) 2009-12-21 2011-06-30 Acef S.A. Cubebina, lignana dibenzilbutirolactólica, seus derivados semi-sintéticos e sintéticos, bem como outras lignanas e neolignanas como agente vasodilatador na terapia da disfunção erétil

Also Published As

Publication number Publication date
US20080214661A1 (en) 2008-09-04
WO2006113981A3 (en) 2006-12-14
EP1917260A2 (en) 2008-05-07
WO2006113981A2 (en) 2006-11-02
JP2008539173A (ja) 2008-11-13
EP1917260A4 (en) 2010-08-18

Similar Documents

Publication Publication Date Title
AR033367A1 (es) Derivados de imidazopirimidina y derivados de triazolopirimidina, un procedimiento para su preparacion, medicamentos, una composicion farmaceutica, y uso de dichos derivados para la preparacion de medicamentos
ATE412417T1 (de) Topische zusammensetzung zur behandlung von psoriasis und verwandten hautkrankheiten
BRPI0609784C1 (pt) compostos éster de n-alquilcarbonil-aminoácido e n-alquilcarbonil-amino lactona, composição, e, uso de um composto
PE20050255A1 (es) Nuevas cianotiazolidas y procedimiento para su preparacion como medicamentos
BRPI0618552B8 (pt) compostos derivados de pirimidina ligados ao oxigênio,composição farmacêutica que inclui os ditos compostos,método de síntese dos compostos e usos terapêuticos dos mesmos
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
HK1102991A1 (en) Pharmaceutical formulation of decitabine
ATE361084T1 (de) Topische pharmazeutische zusammensetzungen mit proanthocyanidinen, glycyrrhetinic säure und telmesteine zur behandlung von dermatitis
ECSP067043A (es) Derivados de pirrolotriazina útiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogénesis
IL154888A (en) Aqueous Pharmaceutical Gel Preparation Containing At least One Vitamin D or One Vitamin D Analog At least One Corticosteroid
BRPI0508177A (pt) composto, processo para a produção do composto, composição farmacêutica, uso do composto método para o tratamento de uma doença e produto de combinação
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
BR0312232A (pt) Inibidores de caspases e seus usos
CY1108932T1 (el) Ενωσεις 4-(ετεροκυκλυλ)-βενζολοσουλφοξιμινης για την θεραπευτικη αγωγη φλεγμονωδων ασθενειων
BRPI0501542A (pt) processo de obtenção de lignanas dibenzilbutirolactÈnicas, tetrahidrofuránicas e de seus derivados sintéticos e semi-sintéticos, suas atividades analgésica e antiinflamatória, formulações tópicas e/ou sistêmicas contendo tais lignanas e respectivo método terapêutico
CY1109507T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ελαστομερες οργανοπολυσιλοξανιο και μια διαλυτοποιημενη δραστικη ουσια
ATE231852T1 (de) Bicyclische aromatische verbindungen
AR004480A1 (es) Compuestos de ascomicina que poseen actividad antiinflamatoria, pro cedimiento para prepararlos, uso de dichos compuestos para preparar agentesfarmaceuticos y composiciones farmaceuticas que los incluyen
WO2008119097A8 (de) Pharmazeutisches mittel gegen juckreiz und schmerz
ATE526015T1 (de) Arzneimittel sowie deren herstellung und verwendung bei der behandlung von schmerzhaften neuropathien
BRPI0607258A2 (pt) uso, composto, bem como formulações farmacêuticas
MA31630B1 (fr) Dérivés de 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamides et de 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazépine-7-carboxamides, leur préparation et leur application en thérapeutique
BRPI0416188A (pt) formulações de medicamentos que contêm aromatizante, com propriedades farmacêuticas aperfeiçoadas
BR0317519A (pt) Composição farmacêutica para anestesia local e uso da mesma
DE60027127D1 (de) Verwendung von Polyaminosäurederivaten zur Behandlung von Seborrhoe und verwandten Hautstörungen

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE A 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013.